natgillin/translations-raw huggingface dataset:
Fortæl det til din PAH-læge eller sundhedspersonalet, hvis du tager et eller flere af følgende lægemidler: - Gemfibrozil (lægemiddel, der anvendes til at sænke niveauet af fedt [lipider] i blodet) - Clopidogrel (lægemiddel, der anvendes til at hæmme dannelsen af blodpropper ved koronararteriesygdom) - Deferasirox (lægemiddel, der anvendes til at fjerne jern fra blodet) - Teriflunomid (lægemiddel, der anvendes til behandling af recidiverende-remitterende multipel sklerose) - Carbamazepin (lægemiddel, der anvendes til behandling af visse former for epilepsi,
Talk to your PAH doctor or nurse if you are taking any of the following medicines: - Gemfibrozil (medicine used to lower the level of fats [lipids] in the blood) - Clopidogrel (medicine used to inhibit blood clots in coronary artery disease) - Deferasirox (medicine used to remove iron from the blood stream) - Teriflunomide (medicine used to treat relapsing-remitting multiple sclerosis) - Carbamazepine (medicine used to treat some forms of epilepsy, nerve pain or to help control serious mood disorders when some other medicines do not work) - Phenytoin (medicine used to treat epilepsy) - Valproic acid (medicine used to treat epilepsy) - Probenecid (medicine used to treat gout) - Fluconazole, rifampicin or rifapentine (antibiotics used to treat infections)
Side 8
Page 8
De mest almindeligt indberettede bivirkninger er hovedpine, diarré, kvalme og opkastning, smerter i kæben, myalgi, ekstremitetssmerter, artralgi og blussen.
The most commonly reported adverse reactions are headache, diarrhoea, nausea and vomiting, jaw pain, myalgia, pain in extremity, arthralgia, and flushing.
I titreringsforløbet kan du få bivirkninger, såsom hovedpine, diarré, kvalme, opkastning, smerter i kæben, muskelsmerter, smerter i benene, ledsmerter eller ansigtsrødme (se afsnit 4).
During titration, you may experience side effects such as headache, diarrhoea, feeling sick (nausea), being sick (vomiting), jaw pain, muscle pain, leg pain, joint pain, or reddening of the face (see section 4).
Er du i tvivl eller har spørgsmål, så spørg lægen.
- If you have any further questions, ask your doctor or nurse.
Når du overgår til din vedligeholdelsesdosis.............14 Hvis du har glemt at tage Uptravi..............................16
When you move to your maintenance dose.............14
....................................10 Nedtrapning..............................................................12
If you forget to take Uptravi.....................................16 If you stop taking Uptravi.........................................17 Titration diary...........................................................18
Din læge vil ordinere en tablet med den for dig individuelt tilpassede styrke, som vil være din vedligeholdelsesdosis.
Your doctor will prescribe a suitable tablet strength for your maintenance dose.
Husk, at du skal være i regelmæssig kontakt med din PAH-læge eller sundhedspersonalet.
Remember to talk to your PAH doctor or nurse regularly.
Ved brug af 400/100 mg lopinavir/ritonavir, en stærk OATP- (OATPB1 og OATP1B3) og P-gphæmmer, to gange dagligt, steg eksponeringen for selexipag til cirka det dobbelte, hvorimod eksponeringen for selexipags aktive metabolit var uforandret.
In the presence of 400/100 mg lopinavir/ritonavir twice daily, a strong OATP (OATP1B1 and OATP1B3) and P-gp inhibitor, exposure to selexipag increased approximately 2-fold, whereas the exposure to the active metabolite of selexipag did not change.
Udslæt Urticaria Erytem
Rash Urticaria Erythema
Vend tilbage til dosering med Uptravi to gange dagligt, når samtidig administration af moderate CYP2C8-hæmmere er ophørt (se pkt.
Revert to twice daily dosing frequency of Uptravi when co-administration of moderate CYP2C8 inhibitor is stopped (see section 4.5).
• Lamineret titreringsvejledning i A4-format til læger og sundhedspersonale.
• Healthcare professional A4 laminated titration guide;
Side 30
Page 30
Ved brug af 600 mg rifampicin, en induktor af CYP2C8 (og UGT-enzymer), én gang dagligt var der ingen forandring i eksponeringen for selexipag, hvorimod eksponeringen for den aktive metabolit blev reduceret til det halve.
In the presence of 600 mg rifampicin, once a day, an inducer of CYP2C8 (and UGT enzymes), the exposure to selexipag did not change, whereas exposure to the active metabolite was reduced by half.
Side 31
Page 31
Side 38
Page 38
Side 5
Page 5
Side 35
Page 35
Side 25
Page 25
Spørg lægen til råds, hvis du har taget flere tabletter, end lægen har anvist.
If you have taken more tablets than you have been told to take, ask your doctor for advice.
Side 23
Page 23
Side 24
Page 24
Side 39
Page 39
Side 36
Page 36
Side 33
Page 33
Brug af anden medicin sammen med Uptravi
Other medicines and Uptravi
Formålet er at nå den dosis, der er mest velegnet til
The goal is to reach the dose that is most appropriate to treat you.
Selexipag hydrolyseres til sin aktive metabolit via carboxylesteraser (se pkt.
Selexipag is hydrolysed to its active metabolite by carboxylesterases (see section 5.2).
Side 12
Page 12
Side 15
Page 15
Side 32
Page 32
Side 28
Page 28
Side 20
Page 20
Side 29
Page 29
Ved samtidig administration af CYP2C8-induktorer (f.eks. rifampicin, carbamazepin, phenytoin) kan det være nødvendigt at justere dosen af selexipag.
Dose adjustment of selexipag may be required with concomitant administration of inducers of CYP2C8 (e.g., rifampicin, carbamazepine, phenytoin).
Side 16
Page 16
Side 9
Page 9
Side 37
Page 37
Side 11
Page 11
Side 40
Page 40
Side 18
Page 18
Ved brug af 600 mg gemfibrozil (en stærk CYP2C8-hæmmer) to gange dagligt steg eksponeringen for selexipag til cirka det dobbelte, hvorimod eksponeringen for den aktive metabolit, som bidrager væsentligt til virkningen, steg cirka 11 gange.
In the presence of 600 mg gemfibrozil, twice a day, a strong inhibitor of CYP2C8, exposure to selexipag increased approximately 2-fold, whereas exposure to the active metabolite, the major contributor to efficacy, increased approximately 11-fold.
Side 22
Page 22
Eksponeringen for selexipag var hhv. 2 og 4 gange højere hos patienter med mild (Child-Pugh-klasse A) eller moderat (Child-Pugh-klasse B) leverinsufficiens end hos raske forsøgsdeltagere.
In subjects with mild (Child-Pugh class A) or moderate (Child-Pugh class B) hepatic impairment, exposure to selexipag was 2- and 4-fold higher, respectively, when compared to healthy subjects.
Antikoagulantia eller trombocytaggregationshæmmere
Anticoagulants or inhibitors of platelet aggregation
Side 10
Page 10
Side 27
Page 27
Side 34
Page 34
Den gennemsnitlige alder var 48,1 år (interval 18-80 år), og størstedelen af forsøgsdeltagerne var kaukasere (65,0 %) og kvinder (79,8 %).
The mean age was 48.1 years (range 18-80 years of age), with the majority of subjects being
Uptravi 200 mikrogram Uptravi 400 mikrogram Uptravi 600 mikrogram Uptravi 800 mikrogram Uptravi 1.000 mikrogram Uptravi 1.200 mikrogram Uptravi 1.400 mikrogram Uptravi 1.600 mikrogram
Uptravi 200 microgram Uptravi 400 microgram Uptravi 600 microgram Uptravi 800 microgram Uptravi 1,000 microgram Uptravi 1,200 microgram Uptravi 1,400 microgram Uptravi 1,600 microgram
Ved brug af 400/100 mg lopinavir/ritonavir (en stærk CYP3A4-hæmmer) to gange dagligt, steg eksponeringen for selexipag til cirka det dobbelte, hvorimod eksponeringen for selexipags aktive metabolit var uforandret.
In the presence of 400/100 mg lopinavir/ritonavir twice daily, a strong CYP3A4 inhibitor, exposure to selexipag increased approximately 2-fold, whereas the exposure to the active metabolite of selexipag did not change.
Individuelt tilpasset dosistitrering
Individualised dose titration
Mave-tarm-kanalen Diarré* Opkastning*
Diarrhoea* Vomiting * Nausea*
Side 19
Page 19
Side 14
Page 14
Uptravi 200 mikrogram filmovertrukne tabletter Kartoner med 10 eller 60 filmovertrukne tabletter og 60 eller 140 filmovertrukne tabletter (titreringspakker).
Cartons of 10 or 60 film-coated tablets, and 60 or 140 film-coated tablets (titration packs).
Side 21
Page 21
Side 13
Page 13
Side 7
Page 7
Side 26
Page 26
Side 4
Page 4
I forbindelse med dosistitrering kan der indtræde bivirkninger, der afspejler Uptravis virkningsmekanisme (såsom hovedpine, diarré, kvalme og opkastning, smerter i kæben, myalgi, ekstremitetssmerter, artralgi og blussen).
During dose titration some adverse reactions, reflecting the mode of action of Uptravi (such as headache, diarrhoea, nausea and vomiting, jaw pain, myalgia, pain in extremity, arthralgia, and flushing), may occur.
Side 6
Page 6
Side 3
Page 3
Hvis du glemmer at tage Uptravi, skal du tage en dosis, så snart du kommer i tanker om det.
If you forget to take Uptravi, take a dose as soon as you remember, then continue to take your tablets at the usual times.
Uptravi 400 mikrogram, 600 mikrogram, 800 mikrogram, 1.000 mikrogram, 1.200 mikrogram, 1.400 mikrogram og 1.600 mikrogram filmovertrukne tabletter leveres i blisterpakninger med 60 tabletter.
Uptravi 400 microgram, 600 microgram, 800 microgram, 1,000 microgram, 1,200 microgram, 1,400 microgram, and 1,600 microgram film-coated tablets are supplied in blister packs of 60 tablets.
Denne dosis øges med ugentlige intervaller i trin af 200 mikrogram givet én gang dagligt, indtil patienten får utålelige eller medicinsk uhåndterbare bivirkninger, der afspejler selexipags virkningsmåde.
For patients with moderate hepatic impairment (Child-Pugh class B), the starting dose of Uptravi should be 200 micrograms once daily, and increased at weekly intervals by increments of 200 micrograms given once daily until adverse reactions, reflecting the mode of action of selexipag, that cannot be tolerated or medically managed are experienced.
Anæmi Hæmoglobin nedsat
Anaemia Haemoglobin decreased
Selexipag hæmmer trombocytaggregationen in vitro.
Selexipag is an inhibitor of platelet aggregation in vitro.
Hver filmovertrukken tablet indeholder 200 mikrogram selexipag
Each film-coated tablet contains 200 micrograms of selexipag
Smerter i kæben* Myalgi*
Pain in jaw Myalgia
Du kan se en komplet liste over bivirkninger i indlægssedlen.
For a full list of side effects see package leaflet for further information.
Uptravi 400 mikrogram, 600 mikrogram, 800 mikrogram, 1.000 mikrogram, 1.200 mikrogram, 1.400 mikrogram og 1.600 mikrogram filmovertrukne tabletter Kartoner med 60 filmovertrukne tabletter.
Uptravi 400 microgram, 600 microgram, 800 microgram, 1,000 microgram, 1,200 microgram, 1,400 microgram, and 1,600 microgram film-coated tablets Cartons of 60 film-coated tablets.
Spørg lægen eller sundhedspersonalet, hvis der er noget, du er i tvivl om.
Check with your doctor if you are not sure or have any questions.
Ved steady state er eksponeringen for den aktive metabolit cirka 3 til 4 gange højere end eksponeringen for moderstoffet, både hos raske forsøgsdeltagere og PAH-patienter efter oral administration.
Both in healthy subjects and PAH patients, after oral administration, exposure at steady state to the active metabolite is approximately 3- to 4-fold higher than to the parent compound.
Det har samme afslappende og udvidende virkning på blodkarrene som det naturlige stof prostacyklin.
It acts on blood vessels in a similar way to the natural substance prostacyclin, making them relax and widen.
Vurderet ud fra den samlede evidens fra udførte genotoksicitetsstudier er selexipag og den aktive metabolit ikke genotoksiske.
Selexipag and the active metabolite are not genotoxic on the basis of the overall evidence of conducted genotoxicity studies.
Hypromellose, propylenglycol, titandioxid (E171), carnaubavoks og jernoxider (se nedenfor).
Hypromellose, propylene glycol, titanium dioxide (E171), carnauba wax and iron oxides (see below).
Artralgi* Smerter i ekstremiteterne*
Jaw pain* Myalgia* Arthralgia* Pain in extremity*
Uptravi 800 mikrogram filmovertrukne tabletter: Runde, grønne, filmovertrukne tabletter, der er mærket med "8" på den ene side.
Uptravi 800 microgram film-coated tablets: Round, green, film-coated tablets with “8” marked on one side.
Der er ingen erfaring med Uptravi hos patienter i dialyse (se pkt.
There is no experience with Uptravi in patients undergoing dialysis (see section 5.2), therefore Uptravi should not be used in these patients.
Uptravi 200 mikrogram tabletter Uptravi 400 mikrogram tabletter Uptravi 600 mikrogram tabletter Uptravi 800 mikrogram tabletter Uptravi 1.000 mikrogram tabletter Uptravi 1.200 mikrogram tabletter Uptravi 1.400 mikrogram tabletter Uptravi 1.600 mikrogram tabletter selexipag
Uptravi 200 microgram tablets Uptravi 400 microgram tablets Uptravi 600 microgram tablets Uptravi 800 microgram tablets Uptravi 1,000 microgram tablets Uptravi 1,200 microgram tablets Uptravi 1,400 microgram tablets Uptravi 1,600 microgram tablets selexipag
Uptravi 1.000 mikrogram filmovertrukne tabletter: Runde, orange, filmovertrukne tabletter, der er mærket med "10" på den ene side.
Uptravi 1,000 microgram film-coated tablets: Round, orange, film-coated tablets with “10” marked on one side.
• Indlægsseddel.
• Patient Leaflet.
Uptravi 800 mikrogram filmovertrukne tabletter Hver filmovertrukken tablet indeholder 800 mikrogram selexipag.
Uptravi 800 microgram film-coated tablets Each film-coated tablet contains 800 micrograms of selexipag.
Uptravi 800 mikrogram filmovertrukne tabletter Runde, grønne, filmovertrukne tabletter, der er præget med "8" på den ene side.
Uptravi 800 microgram film-coated tablets Round, green, film-coated tablets with “8” debossed on one side.
Uptravi 1.000 mikrogram filmovertrukne tabletter Runde, orange, filmovertrukne tabletter, der er præget med "10" på den ene side.
Uptravi 1,000 microgram film-coated tablets Round, orange, film-coated tablets with “10” debossed on one side.
Uptravi 400 mikrogram filmovertrukne tabletter: Runde, røde, filmovertrukne tabletter, der er mærket med "4" på den ene side.
Uptravi 400 microgram film-coated tablets: Round, red, film-coated tablets with “4” marked on one side.
Uptravi 400 mikrogram filmovertrukne tabletter indeholder rød jernoxid (E172).
Uptravi 400 microgram film-coated tablets contain iron oxide red (E172).
Uptravi 1.400 mikrogram filmovertrukne tabletter indeholder gul jernoxid (E172).
Uptravi 1,400 microgram film-coated tablets contain iron oxide yellow (E172).
Uptravi 1.600 mikrogram filmovertrukne tabletter: Runde, brune, filmovertrukne tabletter, der er mærket med "16" på den ene side.
Uptravi 1,600 microgram film-coated tablets: Round, brown, film-coated tablets with “16” marked on one side.
Uptravi 800 mikrogram filmovertrukne tabletter indeholder gul jernoxid og sort jernoxid (E172).
Uptravi 800 microgram film-coated tablets contain iron oxide yellow and iron oxide black (E172).
Uptravi 800 mikrogram filmovertrukne tabletter.
Uptravi 800 microgram film-coated tablets.
Uptravi 200 mikrogram filmovertrukne tabletter Hver filmovertrukken tablet indeholder 200 mikrogram selexipag.
Uptravi 200 microgram film-coated tablets Each film-coated tablet contains 200 micrograms of selexipag.
Uptravi 400 mikrogram filmovertrukne tabletter Runde, røde, filmovertrukne tabletter, der er præget med "4" på den ene side.
Uptravi 400 microgram film-coated tablets Round, red, film-coated tablets with “4” debossed on one side.
Uptravi 200 mikrogram filmovertrukne tabletter indeholder gul jernoxid (E172).
Uptravi 200 microgram film-coated tablets contain iron oxide yellow (E172).
Uptravi 1.000 mikrogram filmovertrukne tabletter Hver filmovertrukken tablet indeholder 1.000 mikrogram selexipag.
Uptravi 1,000 microgram film-coated tablets Each film-coated tablet contains 1,000 micrograms of selexipag.
Uptravi 200 mikrogram filmovertrukne tabletter.
Uptravi 200 microgram film-coated tablets.
Uptravi 1.200 mikrogram filmovertrukne tabletter Hver filmovertrukken tablet indeholder 1.200 mikrogram selexipag.
Uptravi 1,200 microgram film-coated tablets Each film-coated tablet contains 1,200 micrograms of selexipag.
Hvis du glemmer en dosis, skal du tage den, så snart du kommer i tanker om det.
If you miss a dose, take the dose as soon as you remember, then continue to take your tablets at the usual times.
Uptravi 200 mikrogram filmovertrukne tabletter Uptravi 400 mikrogram filmovertrukne tabletter Uptravi 600 mikrogram filmovertrukne tabletter Uptravi 800 mikrogram filmovertrukne tabletter Uptravi 1.000 mikrogram filmovertrukne tabletter Uptravi 1.200 mikrogram filmovertrukne tabletter Uptravi 1.400 mikrogram filmovertrukne tabletter Uptravi 1.600 mikrogram filmovertrukne tabletter
Uptravi 200 microgram film-coated tablets Uptravi 400 microgram film-coated tablets Uptravi 600 microgram film-coated tablets Uptravi 800 microgram film-coated tablets Uptravi 1,000 microgram film-coated tablets Uptravi 1,200 microgram film-coated tablets Uptravi 1,400 microgram film-coated tablets Uptravi 1,600 microgram film-coated tablets selexipag
Uptravi 400 mikrogram filmovertrukne tabletter Hver filmovertrukken tablet indeholder 400 mikrogram selexipag.
Uptravi 400 microgram film-coated tablets Each film-coated tablet contains 400 micrograms of selexipag.
Uptravi 400 mikrogram filmovertrukne tabletter.
Uptravi 400 microgram film-coated tablets.
Uptravi 1.200 mikrogram filmovertrukne tabletter: Runde, mørkelilla, filmovertrukne tabletter, der er mærket med "12" på den ene side.
Uptravi 1,200 microgram film-coated tablets: Round, dark-violet, film-coated tablets with “12” marked on one side.
Uptravi 1.000 mikrogram filmovertrukne tabletter.
Uptravi 1,000 microgram film-coated tablets.
Uptravi 200 mikrogram filmovertrukne tabletter: Runde, lysegule, filmovertrukne tabletter, der er mærket med "2" på den ene side.
Uptravi 200 microgram film-coated tablets: Round, light-yellow, film-coated tablets with “2” marked on one side.
Uptravi 1.400 mikrogram filmovertrukne tabletter.
Uptravi 1,400 microgram film-coated tablets.
Uptravi 1.000 mikrogram filmovertrukne tabletter indeholder rød jernoxid og gul jernoxid (E172).
Uptravi 1,000 microgram film-coated tablets contain iron oxide red and iron oxide yellow (E172).
Uptravi 600 mikrogram filmovertrukne tabletter indeholder rød jernoxid og sort jernoxid (E172).
Uptravi 600 microgram film-coated tablets contain iron oxide red and iron oxide black (E172).
Uptravi 1.200 mikrogram filmovertrukne tabletter indeholder sort jernoxid og rød jernoxid (E172).
Uptravi 1,200 microgram film-coated tablets contain iron oxide black and iron oxide red (E172).
Uptravi 1.200 mikrogram filmovertrukne tabletter.
Uptravi 1,200 microgram film-coated tablets.
Uptravi 1.600 mikrogram filmovertrukne tabletter indeholder sort jernoxid, rød jernoxid og gul jernoxid (E172).
Uptravi 1,600 microgram film-coated tablets contain iron oxide black, iron oxide red and iron oxide yellow (E172).
Uptravi 1.600 mikrogram filmovertrukne tabletter Runde, brune, filmovertrukne tabletter, der er præget med "16" på den ene side.
Uptravi 1,600 microgram film-coated tablets Round, brown, film-coated tablets with “16” debossed on one side.
Uptravi 600 mikrogram filmovertrukne tabletter: Runde, lyselilla, filmovertrukne tabletter, der er mærket med "6" på den ene side.
Uptravi 600 microgram film-coated tablets: Round, light-violet, film-coated tablets with “6” marked on one side.
Uptravi 1.400 mikrogram filmovertrukne tabletter: Runde, mørkegule, filmovertrukne tabletter, der er mærket med "14" på den ene side.
Uptravi 1,400 microgram film-coated tablets: Round, dark-yellow, film-coated tablets with “14” marked on one side.
Uptravi 600 mikrogram filmovertrukne tabletter Hver filmovertrukken tablet indeholder 600 mikrogram selexipag.
Uptravi 600 microgram film-coated tablets Each film-coated tablet contains 600 micrograms of selexipag.
Pulmonal hæmodynamik
Pulmonary haemodynamics
Uptravi 600 mikrogram filmovertrukne tabletter.
Uptravi 600 microgram film-coated tablets.
Smerter i ekstremiteterne Opkastning
Pain in extremity Vomiting Flushing Arthralgia
Udseende og pakningsstørrelser
What Uptravi looks like and contents of the pack
Uptravi 1.400 mikrogram filmovertrukne tabletter Runde, mørkegule, filmovertrukne tabletter, der er præget med "14" på den ene side.
Uptravi 1,400 microgram film-coated tablets Round, dark-yellow, film-coated tablets with “14” debossed on one side.
Uptravi 1.600 mikrogram filmovertrukne tabletter.
Uptravi 1,600 microgram film-coated tablets.
Uptravi 200 mikrogram filmovertrukne tabletter Runde, lysegule, filmovertrukne tabletter, der er præget med "2" på den ene side.
Uptravi 200 microgram film-coated tablets Round, light-yellow, film-coated tablets with “2” debossed on one side.
Uptravi 800 mikrogram filmovertrukket tablet:
Uptravi 800 microgram film-coated tablet
Uptravi 1.400 mikrogram filmovertrukne tabletter indeholder 1.400 mikrogram selexipag.
Uptravi 1,400 microgram film-coated tablets Each film-coated tablet contains 1,400 micrograms of selexipag.
Uptravi 1.200 mikrogram filmovertrukne tabletter Runde, mørkelilla, filmovertrukne tabletter, der er præget med "12" på den ene side.
Uptravi 1,200 microgram film-coated tablets Round, dark-violet, film-coated tablets with “12” debossed on one side.
Hypromellose,
Hepatic impairment
Uptravi 1.000 mikrogram filmovertrukket tablet:
Uptravi 1,000 microgram film-coated tablet
Uptravi 400 mikrogram filmovertrukket tablet:
Uptravi 400 microgram film-coated tablet
Uptravi 1.600 mikrogram filmovertrukne tabletter indeholder 1.600 mikrogram selexipag.
Uptravi 1,600 microgram film-coated tablets Each film-coated tablet contains 1,600 micrograms of selexipag.
Uptravi 1.200 mikrogram filmovertrukket tablet:
Uptravi 1,200 microgram film-coated tablet
Hypromellose, propylenglycol, titandioxid (E171), jernoxid, rød (E172), carnaubavoks.
Hypromellose, propylene glycol, titanium dioxide (E171), iron oxide red (E172), carnauba wax.
Der er begrænset klinisk erfaring med brug af selexipag hos patienter over 75 år.
There is limited clinical experience with selexipag in patients over the age of 75 years, therefore Uptravi should be used with caution in this population (see section 4.2).
Uptravi 1.400 mikrogram filmovertrukket tablet:
Uptravi 1,400 microgram film-coated tablet
Hypromellose, propylenglycol, titandioxid (E171), jernoxid, gul (E172), carnaubavoks.
Hypromellose, propylene glycol, titanium dioxide (E171), iron oxide yellow (E172), carnauba wax.
Uptravi 600 mikrogram filmovertrukket tablet:
Uptravi 600 microgram film-coated tablet
Husk, at du skal være i regelmæssig kontakt med din PAH-læge eller sundhedspersonalet i titreringsforløbet.
doctor or nurse regularly during titration.
Uptravi 1.600 mikrogram filmovertrukket tablet:
Uptravi 1,600 microgram film-coated tablet
Hypromellose, propylenglycol, titandioxid (E171), jernoxid, sort (E172), jernoxid, rød (E172), carnaubavoks.
Hypromellose, propylene glycol, titanium dioxide (E171), iron oxide black (E172), iron oxide red (E172), carnauba wax.
Det skal du vide, før du begynder at tage Uptravi Sådan skal du tage Uptravi Bivirkninger
What Uptravi is and what it is used for What you need to know before you take Uptravi How to take Uptravi
Hypromellose, propylenglycol, titandioxid (E171), jernoxid, rød (E172), jernoxid, gul (E172), carnaubavoks.
Hypromellose, propylene glycol, titanium dioxide (E171), iron oxide red (E172), iron oxide yellow (E172), carnauba wax.
Sådan skal du tage Uptravi
How to take Uptravi
Hæmoglobin nedsat
Tablet core
Hypromellose, propylenglycol, titandioxid (E171), jernoxid, gul (E172), jernoxid , sort (E 172), carnaubavoks.
Hypromellose, propylene glycol, titanium dioxide (E171), iron oxide yellow (E172), iron oxide black (E172), carnauba wax.
Hvad anvendes det til?
What it is used for?
Dato for åbning:___________
Date of opening:___________
Dette er ikke en komplet liste over lægemidler.
This is not a complete list of medicines.
Der gælder de samme anbefalinger, medmindre andet specifikt er angivet.
The same recommendations apply, unless specifically indicated.
Hos nogle patienter blev der givet supplerende faktor VIII.
In some patients additional factor VIII was given.
Brug med forsigtighed.
Use with caution.
Typen af mad er ikke vigtig.
The type of food is not important.
Dato for første markedsføringstilladelse: 26. januar 2018
Date of first authorisation: 26 January 2018
8501 Novo mesto SLOVENIEN
8501 Novo mesto Slovenia
Lægen vil forklare dette for dig.
Your doctor will explain these to you.